Management of desmoid-type fibromatosis involving peripheral nerves

Desmoid-type fibromatosis is an uncommon and aggressive neoplasia, associated with a high rate of recurrence. It is characterized by an infiltrative but benign fibroblastic proliferation occurring within the deep soft tissues. There is no consensus about the treatment of those tumors. We present a surgical series of four cases, involving the brachial plexus (two cases), the median nerve and the medial brachial cutaneous nerve. Except for the last case, they were submitted to multiple surgical procedures and showed repeated recurrences. The diagnosis, the different ways of treatment and the prognosis of these tumoral lesions are discussed. Our results support the indication of radical surgery followed by radiotherapy as probably one of the best ways to treat those controversial lesions.

Analysis of the concordance rates between core needle biopsy and surgical excision in patients with breast cancer

Objective: To evaluate whether immunohistochemical marker studies performed on core needle biopsy (CNB) specimens accurately reflect the marker status of the tumor obtained from final surgical specimen. Methods: This was a retrospective study that used the database of the Division of Mastology of the Hospital das Clinicas, Sao Paulo, Brazil. Sixty-nine patients submitted to ultrasound-guided CNB diagnosed with breast cancer were retrospectively analyzed. Immunohistochemistry (IHC) on core biopsy specimens was compared to that of excisional biopsy regarding estrogen receptor (ER), progesterone receptor (PR), human epidermal gowth factor receptor 2 gene (HER2), p53, and Ki67. The analysis of the concordance between CNB and surgical biopsy was performed using the kappa (k) coefficient (95% CI). Results: A perfect concordance between the labeling in the surgical specimens and the preoperative biopsies in p53 (k = 1.0; 95% CI: 0.76-1.0) was identified. There was an almost perfect concordance for ER (k = 0.89; 95% CI: 0.65-1.0) and a substantial concordance for PR (k = 0.70; 95% CI: 0.46-0.93). HER2 (k = 0.61; 95% CI: 0.38-0.84) and Ki-67 (k = 0.74; 95% CI: 0.58-0.98) obtained a substantial concordance this analysis. Conclusion: The results of this study indicate that the immunohistochemical analysis of ER, PR, Ki-67, and p53 from core biopsy specimens provided results that accurately reflect the marker status of the tumor. The concordance rate of HER2 was less consistent; although it produced substantial concordance, values were very close to moderate concordance.

Fixação zigomática em portadores de fissura de lábio e palato: relato de caso clínico

A técnica de Fixação Zigomática serve como um meio alternativo para pacientes que apresentam grande perda de estrutura maxilar decorrentes de atrofia maxilar severa, traumas, cirurgias ressectivas tumorais ou defeitos congênitos. Pacientes portadores de fissura de lábio e palato podem ser beneficiados com esta técnica, pois apresentam baixo desenvolvimento de seus maxilares devido às cirurgias primárias de queiloplastia e palatoplastia. O implante zigomático de titânio que possui em média 30 mm a 52,5 mm de comprimento, se insere no rebordo alveolar remanescente em direção ao corpo do zigoma. Por meio dessa técnica, é possível ancorar uma prótese fixa utilizando carga precoce. Objetivo: O objetivo deste trabalho foi de relatar um caso ocorrido no Hospital de Reabilitação de Anomalias Craniofaciais, Bauru, São Paulo, com resolução protética de um paciente portador de fissura labiopalatina através da ancoragem zigomática. Relato Clínico: Em 2008, paciente do Hospital de Reabilitação de Anomalias Craniofaciais, portadora de fissura labiopalatina, foi realizado um planejamento criterioso e a opção mais adequada foi a resolução protética através de uma ancoragem em zigoma. Foi utilizado implante zigomático do lado direito e implantes unitários na região dos dos elementos dentários 13 e 11, após exodontia do elemento 11. Assim, confeccionada uma prótese sobre implantes e placa miorrelaxante com controle de 45 dias. Conclusão: Esta alternativa possibilita ao paciente uma menor morbidade, sem a necessidade de cirurgias de reconstrução óssea, apresenta um tempo menor de tratamento e consequentemente integrando o paciente à sociedade.

Tumour cells incorporate exosomes derived from dendritic cells through a mechanism involving the tetraspanin CD9

Exosomes (Exos) are secreted nanovesicles that contain membrane proteins and genetic material, which can be transferred between cells and contribute to their communication in the body. We show that Exos, obtained from mature human dendritic cells (DCs), are incorporated by tumour cells, which after Exos treatment, acquire the expression of HLA‐class I, HLA‐class II, CD86, CD11c, CD54 and CD18. This incorporation reaches its peak eight hours after treatment, can be observed in different cell tumour lines (SK‐BR‐3, U87 and K562) and could be a means to transform non‐immunogenic into immunogenic tumour cells. Interestingly, tetraspanins, which are expressed by the tumour cells, have their surface level decreased after Exo treatment. Furthermore, the intensity of Exo incorporation by the different tumour cell lines was proportional to their CD9 expression levels and pretreatment of Exos with anti‐CD9 decreased their incorporation (by SK‐BR‐3 cells). This modification of tumour cells by DC‐derived Exos may allow their use in new immunotherapeutic approaches to cancer. Furthermore, by showing the involvement of CD9 in this incorporation, we provide a possible selection criterion for tumours to be addressed by this strategy